New Treatment Strategies in Large-vessel Vasculitis
Will biologics have a place in the treatment of large-vessel vasculitis?
medscape.com
Abatacept efficacy differs in trials of Giant Cell and Takayasu’s arteritis
A pair of new studies offer mixed results regarding the use of the rheumatoid arthritis drug abatacept to treat two forms of large-vessel vasculitis: It appears to…
mdedge.com
Abatacept Efficacy Giant Cell Arteritis
A novel trial from Dr. Carol Langford and colleagues has reported the results of a 49 patient trial of newly-diagnosed or relapsing GCA where all patients were treated…
rheumnow.com
Multiple Comorbidity Risks with Giant Cell Arteritis
Elderly patients treated with high doses of corticosteroids are bound to have multiple medical…
rheumnow.com
Causes of Cardiovascular Ischemic Events in Giant Cell Arteritis
Giant cell arteritis (GCA) is a granulomatous vasculitis with rising incidence in the sixth to eighth decade of age, when cardiovascular (CV) events put survival,…
jrheum.org
Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis
Giant cell arteritis (GCA) and the use of glucocorticoids have both been associated with increased risk of venous thromboembolism (VTE). However,…
onlinelibrary.wiley.com
Prior Infections Likely a ‘Minor Determinant’ of Overall GCA Risk
Herpes zoster in particular doesn’t seem to play causal role
medpagetoday.com